Signals Blog
Menu

Update from the Clinic: May

Welcome to your update from the clinic for the month of May. Long-standing industry pioneer StemCells, Inc. decided to wind down its operations after a failed Phase 2 study in spinal cord injury. Aduro Biotech also saw a failure with its GVAX product in pancreatic...

Extracellular vesicles, the next Minions?

This post was authored by Kelvin Ng and James Smith. Completing his PhD this year in the Karp lab at MIT/Harvard, Kelvin focuses on strategies and technologies that guide or accelerate the translation of therapeutic extracellular vesicles. His multidisciplinary...

ISSCR Day 1: Escaping the ground state of pluripotency

The 2016 Annual Meeting of the International Society for Stem Cell Research got off to a fantastic start Wednesday night in San Francisco. Two excellent sessions were delivered to a packed house with talks ranging from the importance of circular RNAs (Pier Paolo...

Cell Therapy Deal Review: May

Welcome to your deal review for the month of May. Intellia Therapeutics went public this past month giving investors a second shot on net if they want to gain exposure to gene editing technologies. Caladrius Biosciences spun-out its cell-based immunotherapy to AiVita...